Unum Therapeutics Inc (NASDAQ:UMRX) Expected to Announce Earnings of -$0.35 Per Share

Analysts predict that Unum Therapeutics Inc (NASDAQ:UMRX) will report earnings per share (EPS) of ($0.35) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Unum Therapeutics’ earnings, with estimates ranging from ($0.48) to ($0.26). Unum Therapeutics posted earnings of ($0.34) per share in the same quarter last year, which suggests a negative year over year growth rate of 2.9%. The business is expected to announce its next quarterly earnings results on Monday, November 11th.

On average, analysts expect that Unum Therapeutics will report full year earnings of ($1.30) per share for the current financial year, with EPS estimates ranging from ($1.42) to ($1.23). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.25) per share, with EPS estimates ranging from ($1.73) to ($0.91). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. The company had revenue of $3.14 million during the quarter, compared to the consensus estimate of $3.10 million.



Several analysts have recently weighed in on UMRX shares. HC Wainwright restated a “buy” rating on shares of Unum Therapeutics in a research report on Tuesday. ValuEngine upgraded shares of Unum Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research report on Friday, April 26th. Wedbush restated an “outperform” rating and set a $13.00 price objective (down previously from $20.00) on shares of Unum Therapeutics in a research report on Tuesday. They noted that the move was a valuation call. Finally, SunTrust Banks lowered their price objective on shares of Unum Therapeutics to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Unum Therapeutics has a consensus rating of “Buy” and a consensus price target of $12.40.

NASDAQ UMRX traded up $0.12 on Thursday, hitting $1.91. The stock had a trading volume of 6,452 shares, compared to its average volume of 202,508. Unum Therapeutics has a 52-week low of $1.75 and a 52-week high of $16.72. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $55.12 million, a P/E ratio of -1.37 and a beta of 1.38. The business has a 50-day moving average of $2.25.

Hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new position in shares of Unum Therapeutics during the 1st quarter valued at $85,000. Acadian Asset Management LLC grew its holdings in shares of Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock valued at $85,000 after purchasing an additional 18,717 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Unum Therapeutics by 251.5% during the 4th quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after purchasing an additional 33,091 shares during the last quarter. D. E. Shaw & Co. Inc. grew its holdings in shares of Unum Therapeutics by 7.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock valued at $242,000 after purchasing an additional 3,846 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Unum Therapeutics by 72.4% during the 4th quarter. Deutsche Bank AG now owns 63,657 shares of the company’s stock valued at $279,000 after purchasing an additional 26,742 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Read More: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.